Evidence map›Paper›PMID 29095972›Full record

ArticleEndocrinology2018

Placental Growth Factor Is Required for Ovulation, Luteinization, and Angiogenesis in Primate Ovulatory Follicles.

Hannah R Bender, Heidi A Trau, Diane M Duffy

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04724343 phase4completednot on this mapstarted 2019, after this paper: background citation

Effect of GnRH Agonist (Long Protocol) vs GnRH Antagonist (Flexible Protocol) on IVF/ICSI Outcomes.

TypeinterventionalSponsorDamascus UniversityRan2019 to 2022Enrolled50ConditionsIn Vitro Fertilization, Intracytoplasmic Sperm Injection, InfertilityArmsTriptorelin acetate, Cetrorelix, recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin, Human Chorionic Gonadotropin (hCG)
NCT04727671 phase4completednot on this mapstarted 2019, after this paper: background citation

Effect of GnRH Agonist (Long Protocol) vs GnRH Antagonist (Flexible Protocol) on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

TypeinterventionalSponsorDamascus UniversityRan2019 to 2021Enrolled50ConditionsIn Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility, Polycystic Ovary SyndromeArmsTriptorelin acetate, Cetrorelix, recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin, Human Chorionic Gonadotropin (hCG)
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Neurotensin modulates ovarian vascular permeability via adherens junctions.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  10. A single-cell gene expression atlas of human follicular aspirates: Identification of leukocyte subpopulations and their paracrine factors.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Neurotensin: A novel mediator of ovulation?FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  17. Newly Identified Regulators of Ovarian Folliculogenesis and Ovulation.International journal of molecular sciences · 2020
    Review
  18. Article
  19. Copper promotion of myocardial regeneration.Experimental biology and medicine (Maywood, N.J.) · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hannah R BenderDepartment of Physiological Sciences, Eastern Virginia Medical School, Norfolk, Virginia.
Heidi A TrauDepartment of Physiological Sciences, Eastern Virginia Medical School, Norfolk, Virginia.
Diane M DuffyDepartment of Physiological Sciences, Eastern Virginia Medical School, Norfolk, Virginia.
Eastern Virginia Medical School · US

Funding

Ovulation and Luteal Formation in Rodents Monkeys and WomenP01HD071875 · NICHD · UNIVERSITY OF KENTUCKY · PI CURRY, THOMAS E · 2014 to 2018
$6.1M
NICHD NIH HHS P01 HD071875
6 · The paper itself

Abstract

Placental growth factor (PGF) is member of the vascular endothelial growth factor (VEGF) family of angiogenesis regulators. VEGFA is an established regulator of ovulation and formation of the corpus luteum. To determine whether PGF also mediates aspects of ovulation and luteinization, macaques received gonadotropins to stimulate multiple follicular development. Ovarian biopsies and whole ovaries were collected before (0 hours) and up to 36 hours after human chorionic gonadotropin (hCG) administration to span the ovulatory interval. PGF and VEGFA were expressed by both granulosa cells and theca cells. In follicular fluid, PGF and VEGFA levels were lowest before hCG. PGF levels remained low until 36 hours after hCG administration, when PGF increased sevenfold to reach peak levels. Follicular fluid VEGFA increased threefold to reach peak levels at 12 hours after hCG, then dropped to intermediate levels. To explore the roles of PGF and VEGFA in ovulation, luteinization, and follicular angiogenesis in vivo, antibodies were injected into the follicular fluid of naturally developed monkey follicles; ovariectomy was performed 48 hours after hCG, with ovulation expected about 40 hours after hCG. Intrafollicular injection of control immunoglobulin G resulted in no retained oocytes, follicle rupture, and structural luteinization, including granulosa cell hypertrophy and capillary formation in the granulosa cell layer. PGF antibody injection resulted in oocyte retention, abnormal rupture, and incomplete luteinization, with limited and disorganized angiogenesis. Injection of a VEGFA antibody resulted in oocyte retention and very limited follicle rupture or structural luteinization. These studies demonstrate that PGF, in addition to VEGFA, is required for ovulation, luteinization, and follicular angiogenesis in primates.

Indexed as

Angiogenesis Inducing AgentsAnimalsFemaleLuteinizationLuteinizing HormoneMacaca fascicularisNeovascularization, PhysiologicOvarian FollicleOvulationPlacenta Growth FactorVascular Endothelial Growth Factor AAngiogenesis Inducing AgentsLuteinizing HormonePlacenta Growth FactorVascular Endothelial Growth Factor A

Identifiers

PMID29095972
PMCPMC5774250
OpenAlexW2766975851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.